The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Highlights from IMS 2024: key clinical trials presented
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, shares his highlights from the 2024 International Myeloma Society (IMS) meeting, outlining some key clinical trials presented at the conference. These include the MIDAS trial (NCT04934475), the AURIGA trial (NCT03901963), and the CEPHEUS trial (NCT03652064). This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
